Last reviewed · How we verify

Nalbuphine in superficial cervical plexus block

Kasr El Aini Hospital · FDA-approved active Small molecule Quality 0/100

Nalbuphine in superficial cervical plexus block is a Small molecule drug developed by Kasr El Aini Hospital. It is currently FDA-approved. Also known as: Nalufin.

At a glance

Generic nameNalbuphine in superficial cervical plexus block
Also known asNalufin
SponsorKasr El Aini Hospital
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Nalbuphine in superficial cervical plexus block

What is Nalbuphine in superficial cervical plexus block?

Nalbuphine in superficial cervical plexus block is a Small molecule drug developed by Kasr El Aini Hospital.

Who makes Nalbuphine in superficial cervical plexus block?

Nalbuphine in superficial cervical plexus block is developed and marketed by Kasr El Aini Hospital (see full Kasr El Aini Hospital pipeline at /company/kasr-el-aini-hospital).

Is Nalbuphine in superficial cervical plexus block also known as anything else?

Nalbuphine in superficial cervical plexus block is also known as Nalufin.

What development phase is Nalbuphine in superficial cervical plexus block in?

Nalbuphine in superficial cervical plexus block is FDA-approved (marketed).

Related